Literature DB >> 10619191

Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects.

H Russ1, T Müller, D Woitalla, A Rahbar, J Hahn, W Kuhn.   

Abstract

The cerebral availability of the peripherally and centrally acting catechol-O-methyltransferase (COMT) inhibitor tolcapone is not known in humans. Therefore, we determined the concentration of tolcapone in cerebrospinal fluid (CSF) of 12 parkinsonian subjects 1-4 h after oral application of 200 mg of the drug. The mean concentration was 56.4+/-35.5 nmol/l (mean +/- SD). This concentration was calculated to cause 75.2+/-15% (mean +/- SD) inhibition of COMT in CSF. Thus, tolcapone efficiently inhibits COMT after crossing the blood-brain barrier in humans.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10619191     DOI： 10.1007/s002109900168

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN： 0028-1298            Impact factor:   3.000


  12 in total

1.  Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.

Authors:  Thomas Müller; Wilfried Kuhn
Journal:  Eur J Clin Pharmacol       Date:  2006-04-22       Impact factor: 2.953

2.  Possible treatment concepts for the levodopa-related hyperhomocysteinemia.

Authors:  Thomas Müller
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-09-09

3.  Synthesis and Evaluation of Heterocyclic Catechol Mimics as Inhibitors of Catechol-O-methyltransferase (COMT).

Authors:  Scott T Harrison; Michael S Poslusney; James J Mulhearn; Zhijian Zhao; Nathan R Kett; Jeffrey W Schubert; Jeffrey Y Melamed; Timothy J Allison; Sangita B Patel; John M Sanders; Sujata Sharma; Robert F Smith; Dawn L Hall; Ronald G Robinson; Nancy A Sachs; Pete H Hutson; Scott E Wolkenberg; James C Barrow
Journal:  ACS Med Chem Lett       Date:  2015-01-26       Impact factor: 4.345

Review 4.  Adjunctive Therapies in Parkinson's Disease: How to Choose the Best Treatment Strategy Approach.

Authors:  Margherita Fabbri; Mario M Rosa; Joaquim J Ferreira
Journal:  Drugs Aging       Date:  2018-12       Impact factor: 3.923

Review 5.  Catechol-O-methyltransferase inhibitors in Parkinson's disease.

Authors:  Thomas Müller
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

Review 6.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  Tolcapone addition improves Parkinson's disease associated nonmotor symptoms.

Authors:  Thomas Müller
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

8.  Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.

Authors:  Siegfried Muhlack; Lennard Herrmann; Stephan Salmen; Thomas Müller
Journal:  J Neural Transm (Vienna)       Date:  2014-04-26       Impact factor: 3.575

9.  Optimization of 8-Hydroxyquinolines as Inhibitors of Catechol O-Methyltransferase.

Authors:  Ingrid Buchler; Daniel Akuma; Vinh Au; Gregory Carr; Pablo de León; Michael DePasquale; Glen Ernst; Yifang Huang; Martha Kimos; Anna Kolobova; Michael Poslusney; Huijun Wei; Dominique Swinnen; Florian Montel; Florence Moureau; Emilie Jigorel; Monika-Sarah E D Schulze; Martyn Wood; James C Barrow
Journal:  J Med Chem       Date:  2018-10-19       Impact factor: 7.446

10.  Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference.

Authors:  Thomas Müller
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.